Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
Researchers at Xencor have slammed the brakes on recruiting more patients for an early-stage study of XmAb14045, a CD123 x CD3 bispecific antibody in the race for acute myeloid leukemia.
The company says that the FDA dropped the hold on them after they tracked 2 deaths in the study that could be linked to the bispecific — one from cytokine release syndrome and another from acute pulmonary edema following several doses. The CRS case was complicated by the patient’s decision to withdraw from the study, according to the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.